文献速递淋巴瘤

晚期霍奇金淋巴瘤一线治疗的成本效果建模研究

Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
PubMed 文献 · Lancet Haematol · 2020-01-13

该建模研究采用马尔可夫决策分析模型,比较五种现代一线治疗方案对适合移植的晚期霍奇金淋巴瘤患者的成本效果。结果显示,基于AHL2011的PET适应性降阶梯策略在支付意愿阈值5万加元下具有87%的成本效果优势,生命年和质量调整生命年最高且直接成本最低。

要点

  • PET适应性降阶梯策略(BEACOPP起始,按PET调整降阶梯至ABVD)最具成本效果。
  • 敏感性分析显示模型对治疗相关死亡率、复发等关键变量稳健。

核心结论

  • 对于新诊断晚期霍奇金淋巴瘤患者,综合考虑成本、效果及短期和长期毒性,首选PET适应性降阶梯方案(BEACOPP起始,酌情降阶梯至ABVD)。

研究设计与样本

  • 采用马尔可夫决策分析模型,时间跨度20年,基于五项临床试验的随机分组共4255例患者(2000年4月至2016年1月入组)。

主要发现

  • 敏感性分析表明模型对治疗相关死亡概率、复发、第二恶性肿瘤频率、第二恶性肿瘤死亡及BEACOPP后不育概率等关键变量稳健。

关键数值与推荐

  • 比较的五种策略包括:6周期ABVD;6周期BEACOPP(HD15或HD18 PET适应性);PET适应性升级(RATHL);6周期A-AVD或ABVD(Echelon-1);PET适应性降阶梯(AHL2011)。
  • 所有方案中使用的BEACOPP均为BEACOPPescalated。

临床怎么用

  • 结果可为临床医生与患者共同决策提供参考,但并非所有患者的绝对最佳方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several strategies are available for the initial treatment of advanced-stage Hodgkin lymphoma, but the optimal strategy in terms of cost-effectiveness is unclear. The aim of this study was to compare the quality-adjusted effectiveness and costs of five modern treatment options for transplantation-eligible patients with newly diagnosed advanced-stage Hodgkin lymphoma. METHODS: A Markov decision-analytic model was developed using a 20-year time horizon. Five of the most common treatment approaches were selected based on clinical experience and expert opinion: (1) six cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), including data from the HD2000 trial, Viviani and colleagues, and EORTC trial; (2) six cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP; from the HD15 trial or PET-adapted as in the HD18 trial, two initial cycles of BEACOPP followed by four additional cycles for patients with a positive PET and either two or four additional cycles of BEACOPP for patients with a negative PET); (3) PET-adapted escalation (as in the RATHL trial, two cycles of standard ABVD chemotherapy followed by an additional four cycles of ABVD or AVD in PET-negative patients and four cycles of BEACOPP in PET-positive patients); (4) six cycles of brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A-AVD) or ABVD as in the Echelon-1 trial; and (5) PET-adapted de-escalation (as in the AHL2011 trial, two cycles of BEACOPP followed by PET2 scan; PET-positive patients received two additional BEACOPP cycles and PET-negative patients received two cycles of ABVD; at PET4, PET-negative patients completed two further cycles of either ABVD or BEACOPP depending on what they received after PET2, and PET-positive patients received salvage therapy). Note that all uses of BEACOPP in these strategies were BEACOPPescalated. The randomised groups of interest from these studies comprised 4255 patients enrolled between April, 2000, and January, 2016. Baseline probability estimates and utilities were derived from the included trials in addition to a systematic review of published studies. A Canadian public health payer's perspective was considered (CAN$1=US$0·74) and adjusted for inflation for 2018. All costs and benefits were discounted by 1·5% per year because life-years now are more valuable than future potential life-years. FINDINGS: Probabilistic analyses (10 000 simulations) showed that, for a willingness-to-pay threshold of CAN$50 000, a PET-adapted de-escalation strategy based on AHL2011 was more cost-effective 87% of the time. This strategy had the highest number of life-years (14·6 years [95% CI 13·7-15·1]) and quality-adjusted life years (13·2 years [95% CI 10·2-14·4]), and the lowest direct costs ($53 129 [95% CI 31 914-94 446]) compared with the other treatment regimens. Sensitivity analyses showed that the model was robust to key variables, including probability of treatment-related mortality, relapse, frequency of secondary malignancy, death from secondary malignancy, and probability of infertility after BEACOPP. INTERPRETATION: Our results suggest that, when considering cost, effectiveness, and short and long-term toxicities, the preferred treatment strategy for patients with newly diagnosed advanced-stage Hodgkin lymphoma is the PET-adapted de-escalation regimen starting with BEACOPP and de-escalating to ABVD as appropriate. Although our findings do not provide an absolute best treatment approach for clinicians to follow for all patients, they can contribute to shared decision making between patients and treating physicians. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Vijenthira A, Chan K, Cheung MC, et al. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol. 2020. PMID: 31948928. doi:10.1016/S2352-3026(19)30218-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。